AR065039A1 - Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso - Google Patents

Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso

Info

Publication number
AR065039A1
AR065039A1 ARP080100316A ARP080100316A AR065039A1 AR 065039 A1 AR065039 A1 AR 065039A1 AR P080100316 A ARP080100316 A AR P080100316A AR P080100316 A ARP080100316 A AR P080100316A AR 065039 A1 AR065039 A1 AR 065039A1
Authority
AR
Argentina
Prior art keywords
release
weight
active agent
composition
amount
Prior art date
Application number
ARP080100316A
Other languages
English (en)
Inventor
Sanjay Boldhane
Kour Chand Jindal
Rajesh Jain
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR065039A1 publication Critical patent/AR065039A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas de liberacion modificada que comprenden por lo menos un agente(s) farmacéuticamente activo(s) que posee una solubilidad que depende del pH, por lo menos un polímero(s) controlador de la tasa de liberacion que predominantemente controla la liberacion de agente(s) activos en un medio acídico, un sistema modificador de la tasa de liberacion que controla la liberacion del agente(s) activo(s) en medios acídicos y básicos, y opcionalmente uno o más de otros excipientes farmacéuticamente aceptables. También se provee un proceso para la preparacion de tales composiciones y el método para su utilizacion. Las composiciones de liberacion modificada de la presente invencion son de utilidad para proveer niveles profilácticamente o terapéuticamente eficaces de agente(s) activo(s) durante un período de tiempo prolongado. Reivindicacion 1: Una composicion farmacéutica de liberacion modificada caracterizada porque comprende al menos un agente(s) farmacéuticamente activo que tiene una solubilidad dependiente del pH, un polímero controlador de la lasa de liberacion que predominantemente controla la liberacion del agente activo en un medio acídico en una cantidad de 3-80% peso/peso de la composicion, un sistema modificador de la tasa de liberacion que controla la liberacion del agente activo en los medios acídicos y básicos que consiste en una combinacion de al menos un agente gelificante in situ en una cantidad no menor de aproximadamente 0,5% peso/peso de la composicion, al menos un agente facilitador de la gelacion en una cantidad de 2-17,5% peso/peso de la composicion y opcionalmente al menos un polímero controlador de la tasa independiente del pH en una cantidad de hasta 40% peso/peso de la composicion y opcionalmente uno o más de otros excipientes farmacéuticamente aceptables.
ARP080100316A 2007-01-25 2008-01-25 Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso AR065039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN164DE2007 2007-01-25

Publications (1)

Publication Number Publication Date
AR065039A1 true AR065039A1 (es) 2009-05-13

Family

ID=39644166

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100316A AR065039A1 (es) 2007-01-25 2008-01-25 Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso

Country Status (11)

Country Link
US (1) US20100056493A1 (es)
EP (1) EP2114380A1 (es)
JP (1) JP2010532746A (es)
KR (1) KR20090109113A (es)
CN (1) CN101588794A (es)
AR (1) AR065039A1 (es)
BR (1) BRPI0807807A2 (es)
CL (1) CL2008000219A1 (es)
MX (1) MX2009007913A (es)
RU (1) RU2009131931A (es)
WO (1) WO2008090569A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529142A (ja) 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
US20110052648A1 (en) * 2008-03-12 2011-03-03 Avi Avramoff Oral modified-release formulations containing thiazepines
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
EP2309994A2 (en) * 2008-07-01 2011-04-20 Lupin Limited Sustained release pharmaceutical compositions comprising quetiapine
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010066342A1 (en) * 2008-11-26 2010-06-17 Krka Quetiapine composition
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) * 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
CN102151242B (zh) * 2010-02-11 2012-10-31 中国医学科学院药用植物研究所 一种抗结核药物的原位凝胶缓释制剂及其制备方法
PT2549983E (pt) * 2010-03-25 2015-06-17 Aop Orphan Pharmaceuticals Ag Nova composiçao para o tratamento de trombocitemia essencial
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
JP2013528213A (ja) 2010-06-07 2013-07-08 テリック，インコーポレイテッド エザチオスタットの錠剤製剤
CN102939300A (zh) 2010-06-07 2013-02-20 泰立克公司 无溶剂化晶体依泽替米贝盐酸盐d型的制备
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102335155B (zh) * 2011-10-17 2013-03-27 苏州大学 一种富马酸喹硫平缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
US9271937B2 (en) * 2012-05-31 2016-03-01 Covidien Lp Oxidized cellulose microspheres
KR101462065B1 (ko) * 2012-12-14 2014-11-14 박재돈 구안파신 함유 경구용 서방성 약제학적 조성물
US9795569B2 (en) 2013-03-15 2017-10-24 Allergan Pharmaceuticals International Limited Pharmaceutical soft gelatin capsule dosage form with modified guar gum
HUE029575T2 (en) * 2013-05-02 2017-03-28 Cardionovum Gmbh Surface-coated balloon
WO2016198166A1 (en) * 2015-06-10 2016-12-15 Disphar International B.V. Improved pharmaceutical formulation
CN106038506A (zh) * 2016-07-20 2016-10-26 南京正宽医药科技有限公司 一种富马酸喹硫平片及其制备方法
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
CN110662533A (zh) 2017-03-13 2020-01-07 奥卡瓦制药公司 向非人哺乳动物递送霉酚酸活性剂的方法和组合物
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN115120590A (zh) * 2022-06-07 2022-09-30 复旦大学 一种以难溶盐为pH调节剂的凝胶缓释制剂及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
EA200800162A1 (ru) * 2005-06-29 2008-06-30 Панацея Биотек Лтд. Новые фармацевтические композиции с замедленным высвобождением и способы их получения

Also Published As

Publication number Publication date
CN101588794A (zh) 2009-11-25
US20100056493A1 (en) 2010-03-04
BRPI0807807A2 (pt) 2014-06-17
WO2008090569A1 (en) 2008-07-31
MX2009007913A (es) 2009-07-31
EP2114380A1 (en) 2009-11-11
CL2008000219A1 (es) 2008-05-16
RU2009131931A (ru) 2011-02-27
KR20090109113A (ko) 2009-10-19
JP2010532746A (ja) 2010-10-14

Similar Documents

Publication Publication Date Title
AR065039A1 (es) Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
AR072544A1 (es) Metodo anticonceptivo mejorado. sistema de suministro. uso. progestageno
MX2009003735A (es) Composicion en deposito inyectable y su procedimiento de preparacion.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
NZ604026A (en) Injectable flowable composition comprising buprenorphine
BRPI0611400B8 (pt) formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
MY167123A (en) Conveniently implantable sustained release drug compositions
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
RS53890B1 (en) STABILIZED POLYMER DELIVERY SYSTEM
PE20040418A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
WO2007084460A3 (en) Pharmaceutical compositions with enhanced stability
MY143795A (en) Tetrahydropyridoindole derivatives
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
PL1750862T3 (pl) Kompozycja farmaceutyczna zawierająca irbesartan
MX2010003923A (es) Formulacion farmaceutica de valsartan.
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
CY1114311T1 (el) Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
HK1108633A1 (en) Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal